Competitive pressure in the US market is forcing some Indian companies to rethink their product portfolios including in the complex generics space, once considered a relatively safe haven in terms of both number of participants vying for a share of the pie and intensity of price erosion.
Glenmark Pharmaceuticals Ltd. said it was no longer pursuing development of four in-licensed complex generic assets as the “overall...







